Analytical Data
-
Gene name
C17L
- Application
-
Alternative Names
(37 kDa protein)(Palmitoylated EV membrane protein)(p37K)
-
Species
Variola virus
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P33815
-
Expression Region
1-372aa
-
Molecular Weight
49.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
C17L recombinant protein, derived from the Orthopoxvirus species, has garnered significant attention in the field of molecular biology and immunology due to its unique properties and potential applications. This protein is a part of the viral immune evasion strategy, as it is known to inhibit various host immune responses, particularly by interfering with the signaling pathways that lead to the production of pro-inflammatory cytokines. Understanding the structure and function of C17L is critical for elucidating how poxviruses evade host immunity, which could pave the way for the development of novel therapeutic strategies and vaccines. Recent studies have focused on characterizing the protein's interactions with host cell receptors and its role in modulating the immune response. Additionally, the potential for C17L as a target for antiviral drug development is being explored, especially in light of emerging viral threats and the need for effective countermeasures. The recombinant production of C17L allows researchers to study its properties in detail, facilitating a deeper understanding of its biological functions and therapeutic potential. Thus, C17L is an important focus of research for understanding virus-host interactions and developing innovative approaches to combat viral infections.
